Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...

Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Liposomal Doxorubicin Market Liposomal Doxorubicin Market Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Liposomal ...

Padma Bhushan awardee folk singer Sharda Sinha left for her heavenly abode on November 5, 2024, after her seven-year-long ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...